Teva Receives FDA Approval for Monthly Schizophrenia Injection
Translated & summarized from Bizportal by baba
Teva Pharmaceuticals has received FDA approval for WELTRUZA, a new monthly subcutaneous injection for schizophrenia patients. The drug offers improved convenience by eliminating the need for post-injection monitoring and concurrent oral medication. Clinical trials showed WELTRUZA effectively improved symptoms and patient functioning. This approval is a significant step in Teva's strategy to focus on innovative branded drugs, with analysts predicting substantial market potential.
The story in 6 lines · by baba
- Teva's WELTRUZA, a monthly schizophrenia injection, received FDA approval for U.S. market entry.
- The new injection offers improved patient convenience by removing the need for post-injection monitoring.
- Clinical trials demonstrated WELTRUZA's effectiveness in treating schizophrenia symptoms and improving patient function.
- WELTRUZA utilizes a novel polymer technology for controlled drug release, mitigating risks of prior injectables.
- The drug's approval is a key component of Teva's strategic shift towards innovative branded pharmaceuticals.
- Analysts project significant annual sales for WELTRUZA, with estimates varying widely.
The U.S. Food and Drug Administration (FDA) has approved Teva Pharmaceuticals' WELTRUZA, a new monthly subcutaneous injection for adults with schizophrenia. The drug, containing the active ingredient olanzapine, will be available in the U.S. in the coming weeks in three dosages: 318, 425, and 531 milligrams. This approval follows Teva's submission in late 2025 and comes in less than a year.
WELTRUZA offers a significant advantage over existing long-acting injectable antipsychotics, particularly Eli Lilly's intramuscular Zyprexa Relprevv. The latter carries a risk of rapid drug release leading to a serious condition called PDSS, requiring patients to remain under medical supervision for at least three hours post-injection. WELTRUZA, utilizing a polymer developed by MedinCell, is designed for slower, consistent release, eliminating the need for post-injection monitoring, loading doses, or concurrent oral medication in the initial weeks.
Clinical trials, including the SOLARIS study involving 675 patients, demonstrated WELTRUZA's efficacy in improving schizophrenia symptoms, reducing severity, and enhancing patients' social and functional abilities. Common side effects were similar to oral olanzapine, including weight gain, drowsiness, and headache, with a 5% discontinuation rate due to side effects, slightly higher than the 4% in the placebo group.
This approval is a key part of Teva's "Pivot to Growth" strategy, shifting focus from generics to innovative branded drugs. While Teva's overall revenue saw a slight dip in the second quarter, its core branded products, including UZEDY (a risperidone injection launched in 2023), showed significant growth. Analysts have varying projections for WELTRUZA's market potential, with estimates ranging from $400 million to over $1 billion annually.
Schizophrenia affects approximately 2.1 million Americans, and adherence to daily oral medication remains a major challenge, making monthly injections a critical treatment option. WELTRUZA aims to address this by providing a convenient and effective long-term treatment, complementing Teva's existing UZEDY injection for schizophrenia and bipolar I disorder.
Mentioned
